Literature DB >> 7882284

p53 mutations, O6-alkylguanine DNA alkyltransferase activity, and sensitivity to procarbazine in human brain tumors.

S J Russell1, Y W Ye, P G Waber, M Shuford, S C Schold, P D Nisen.   

Abstract

BACKGROUND: In human brain tumors, sensitivity to procarbazine as measured by sensitivity in a xenograft tumor model correlated inversely with amounts of the DNA repair enzyme O6-alkylguanine DNA alkyltransferase (AT).
METHODS: To test the hypothesis that mutations of the p53 tumor suppressor gene in human tumors also can correlate with the response to chemotherapy, p53 mutations2 were identified in primary human malignant brain tumors and cell lines in which AT activity and procarbazine sensitivity in a xenograft model was ascertained.
RESULTS: Mutations were identified in 7 of 21 (33%) specimens tested. Specimens containing p53 mutations tended to exhibit an increased growth delay in procarbazine-treated xenografts and lower amounts of AT.
CONCLUSIONS: p53 mutations in brain tumors may contribute to procarbazine sensitivity by failing to induce arrest at the G1/S cell-cycle checkpoint, thereby preventing the repair of procarbazine-induced genetic alterations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7882284     DOI: 10.1002/1097-0142(19950315)75:6<1339::aid-cncr2820750616>3.0.co;2-f

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Sensitivity of human glioma U-373MG cells to radiation and the protein kinase C inhibitor, calphostin C.

Authors:  M Acevedo-Duncan; J Pearlman; B Zachariah
Journal:  Cell Prolif       Date:  2001-02       Impact factor: 6.831

2.  Tumor suppression and inhibition of aneuploid cell accumulation in human brain tumor cells by ectopic overexpression of the cyclin-dependent kinase inhibitor p27KIP1.

Authors:  J Chen; T Willingham; M Shuford; P D Nisen
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

3.  Homeostatic responses of colonic LGR5+ stem cells following acute in vivo exposure to a genotoxic carcinogen.

Authors:  Eunjoo Kim; Laurie A Davidson; Roger S Zoh; Martha E Hensel; Bhimanagouda S Patil; Guddadarangavvanahally K Jayaprakasha; Evelyn S Callaway; Clinton D Allred; Nancy D Turner; Brad R Weeks; Robert S Chapkin
Journal:  Carcinogenesis       Date:  2015-12-30       Impact factor: 4.944

4.  Effects of the PKC inhibitor PD 406976 on cell cycle progression, proliferation, PKC isozymes and apoptosis in glioma and SVG-transformed glial cells.

Authors:  C Russell; M Acevedo-Duncan
Journal:  Cell Prolif       Date:  2005-04       Impact factor: 6.831

5.  Human glioma PKC-iota and PKC-betaII phosphorylate cyclin-dependent kinase activating kinase during the cell cycle.

Authors:  M Acevedo-Duncan; R Patel; S Whelan; E Bicaku
Journal:  Cell Prolif       Date:  2002-02       Impact factor: 6.831

6.  Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells.

Authors:  D M O'Rourke; G D Kao; N Singh; B W Park; R J Muschel; C J Wu; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

7.  DNA ligase IV as a new molecular target for temozolomide.

Authors:  Natsuko Kondo; Akihisa Takahashi; Eiichiro Mori; Ken Ohnishi; Peter J McKinnon; Toshisuke Sakaki; Hiroyuki Nakase; Takeo Ohnishi
Journal:  Biochem Biophys Res Commun       Date:  2009-07-15       Impact factor: 3.575

8.  Chemosensitivity of human malignant glioma: modulation by p53 gene transfer.

Authors:  M Trepel; P Groscurth; U Malipiero; E Gulbins; J Dichgans; M Weller
Journal:  J Neurooncol       Date:  1998-08       Impact factor: 4.130

9.  DNA damage induced by alkylating agents and repair pathways.

Authors:  Natsuko Kondo; Akihisa Takahashi; Koji Ono; Takeo Ohnishi
Journal:  J Nucleic Acids       Date:  2010-11-21

10.  O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies.

Authors:  Ken Sasai; Tsuyoshi Akagi; Eiko Aoyanagi; Kouichi Tabu; Sadao Kaneko; Shinya Tanaka
Journal:  Mol Cancer       Date:  2007-06-05       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.